跳至主要内容
临床试验/NL-OMON51360
NL-OMON51360招募中2 期

68Ga-SATO in paediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study - GAP NBL study* - 68Ga-SATO antagonist in neuroblastoma

Prinses Máxima Centrum voor Kinderoncologie0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 17(—)

入选标准

  • - Age 0-18 years
  • - Written informed consent (by legal representative) and assent consent from
  • the patient when applicable
  • - Patients with a clinical suspicion of neuroblastoma who are referred for the
  • first time for conventional M123IBG imaging and patients with known NBL who are
  • referred for for follow-up M123IBG imaging

排除标准

  • - Children with pre-existing severe auto-immune diseases.
  • - Use of therapeutic long-acting somatostatin analogs (e.g. Sandostatin®,
  • Lanreotide®) within the 21 days before the planned infusion of 68Ga-SATO.
  • - Use of diuretics within 24 hours before the planned infusion of 68Ga-SATO.
  • - pregnancy of the patient

研究者

发起方
Prinses Máxima Centrum voor Kinderoncologie

相似试验